Announcements Trials
Browse Landscape

Phase

Phase 1 20Phase 1/2 4Phase NA 3Phase 2 3

Status

Recruiting 9Unknown 4Completed 4Terminated 3Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Breast Neoplasms 264Carcinoma, Non-Small-Cell Lung 219Neoplasms 218Leukemia, Myeloid, Acute 193Multiple Myeloma 178Colorectal Neoplasms 175Melanoma 165Prostatic Neoplasms 163Lymphoma 145Leukemia 142Lymphoma, Non-Hodgkin 133Glioblastoma 131Pancreatic Neoplasms 127Neoplasm Metastasis 118Lung Neoplasms 118Leukemia, Lymphocytic, Chronic, B-Cell 118Ovarian Neoplasms 112Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Recurrence 97Myelodysplastic Syndromes 93Hodgkin Disease 92Lymphoma, Large B-Cell, Diffuse 89Lymphoma, Follicular 89Lymphoma, Mantle-Cell 83Head and Neck Neoplasms 79Carcinoma, Renal Cell 79Brain Neoplasms 77Sarcoma 73Carcinoma, Hepatocellular 73Squamous Cell Carcinoma of Head and Neck 71

Interventions

pembrolizumab 1Therapeutics 1Jupiter 1Interleukin-2 1Immune Checkpoint Inhibitors 1EBI-005 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Solid Tumor, Adult × Clear all
NCT05307874 2025-12-24

EVICTION-2

ImCheck Therapeutics

Phase 1/2 Completed
56 enrolled
Other solid neoplasm

Solid Tumor, Adult

NCT04597541 2025-03-10

A Study of AK112 for Advanced Solid Tumors

Akeso

Phase 1/2 Completed
59 enrolled
Other solid neoplasm

Solid Tumor, Adult

NCT04020185 2024-12-11

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

ImmuneSensor Therapeutics Inc.

Phase 1/2 Completed
40 enrolled 16 charts
Other solid neoplasm

Solid Tumor, Adult

NCT04121442 2024-08-06

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

Buzzard Pharmaceuticals

Phase 1/2 Completed
15 enrolled
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡